What Happened? A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that ...

BofA lowered the firm’s price target on Organon (OGN) to $11 from $15 and keeps an Underperform rating on the shares. The firm, in its preview ...

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Organon (OGN – Research Report) today and set a price target of ...

Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Organon (NYSE:OGN) jumped 7%. Is now the time to buy Organon? Access our full analysis report here, it’s free.